Hesperidin suppresses ERS-induced inflammation in the pathogenesis of non-alcoholic fatty liver disease

Xie, Qi; Gao, Shuqing; Lei, Min; Li, Zengning

doi:10.18632/aging.203817

Cited by 22 publications

(11 citation statements)

References 47 publications

(50 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has antioxidation, inhibits inflammation, and improves the molecular mechanism of glucose and lipid metabolism through AMPK/peroxisome proliferator-activated receptor-Gamma coactivator 1 Alpha (PGC-1a) and PPAR signaling pathways (138)(139)(140). In addition, studies have shown that HSP can significantly inhibit endoplasmic reticulum stress in oxidative stress in NAFLD models in vivo and in vitro (141). In this systematic review, Yari et al found that compared with the control group, hesperidin+flaxseed, hesperidin, and flaxseed could reduce plasma ALT levels and HOMA-IR, fasting blood glucose, and fatty liver index.…”

Section: Hesperidinmentioning

confidence: 91%

Efficacy and safety of dietary polyphenol supplementation in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis

Yang

Chen²,

Zhang³

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

BackgroundDietary polyphenol treatment of non-alcoholic fatty liver disease (NAFLD) is a novel direction, and the existing clinical studies have little effective evidence for its therapeutic effect, and some studies have inconsistent results. The effectiveness of dietary polyphenols in the treatment of NAFLD is still controversial. The aim of this study was to evaluate the therapeutic efficacy of oral dietary polyphenols in patients with NAFLD.MethodsThe literature (both Chinese and English) published before 30 April 2022 in PubMed, Cochrane, Medline, CNKI, and other databases on the treatment of NAFLD with dietary polyphenols was searched. Manual screening, quality assessment, and data extraction of search results were conducted strictly according to the inclusion and exclusion criteria. RevMan 5.3 software was used to perform the meta-analysis.ResultsThe RCTs included in this study involved dietary supplementation with eight polyphenols (curcumin, resveratrol, naringenin, anthocyanin, hesperidin, catechin, silymarin, and genistein) and 2,173 participants. This systematic review and meta-analysis found that 1) curcumin may decrease body mass index (BMI), Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Triglycerides (TG) total cholesterol (TC), and Homeostasis Model Assessment-Insulin Resistance (HOMA-IR) compared to placebo; and curcumin does not increase the occurrence of adverse events. 2) Although the meta-analysis results of all randomized controlled trials (RCTs) did not reveal significant positive changes, individual RCTs showed meaningful results. 3) Naringenin significantly decreased the percentage of NAFLD grade, TG, TC, and low-density lipoprotein cholesterol (LDL-C) and increased high-density lipoprotein cholesterol (HDL-C) but had no significant effect on AST and ALT, and it is a safe supplementation. 4) Only one team presents a protocol about anthocyanin (from Cornus mas L. fruit extract) in the treatment of NAFLD. 5) Hesperidin may decrease BMI, AST, ALT, TG, TC, HOMA-IR, and so on. 6) Catechin may decrease BMI, HOMA-IR, and TG level, and it was well tolerated by the patients. 7) Silymarin was effective in improving ALT and AST and reducing hepatic fat accumulation and liver stiffness in NAFLD patients.ConclusionBased on current evidence, curcumin can reduce BMI, TG, TC, liver enzymes, and insulin resistance; catechin can reduce BMI, insulin resistance, and TG effectively; silymarin can reduce liver enzymes. For resveratrol, naringenin, anthocyanin, hesperidin, and catechin, more RCTs are needed to further evaluate their efficacy and safety.

show abstract

Section: Hesperidinmentioning

confidence: 91%

Efficacy and safety of dietary polyphenol supplementation in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis

Yang

Chen²,

Zhang³

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…The tissues were observed using an optical microscope (Carl Zeiss AG). Finally, the relative level of lipids was calculated as the Oil Red O‐stained area divided by total cell area and analyzed by ImageJ software [23].…”

Section: Methodsmentioning

confidence: 99%

Rutaecarpin reduces lipids by DGKθ‐dependent activation of PPARα

Wang

Chang

et al. 2022

Obesity

View full text Add to dashboard Cite

ObjectiveLipid metabolic disorders pose a serious threat to human health, and currently no good treatments exist. In earlier studies by the authors, HepG2 cells with diacylglycerol kinase theta (DGKθ) knockout were found to cause significant lipid accumulation, suggesting that DGKθ may be a potential target for treating lipid metabolic disorders.MethodsA high‐throughput screening of natural products targeting the potential signaling pathway of lipid metabolism was carried out in the DGKθ‐T2A‐luciferase knock‐in HepG2 cell. RNA‐sequencing and bioinformatic approaches were used to analyze the potential pathway by which rutaecarpin decreases lipids. Western blot and quantitative polymerase chain reaction were performed to investigate the mechanisms of rutaecarpin's reduction in lipid levels.ResultsRutaecarpin was found to significantly enhance DGKθ expression, and the potential mechanisms by which rutaecarpin accelerates lipid metabolism by targeting DGKθ was explored in vitro and in vivo. The results indicated that rutaecarpin could markedly reduce lipid accumulation in oleic acid‐induced HepG2 cells and in high‐fat diet‐induced obese C57BL/6J mice by targeting the hepatocyte nuclear factor 1‐beta (HNF1B)‐DGKθ‐peroxisome proliferator‐activated receptor alpha (PPARα)‐apolipoprotein C3 (APOC3) pathway.ConclusionRutaecarpin is effective in reducing lipid accumulation, and the development of a high‐throughput screening platform based on a reporter knock‐in cell line may facilitate the discovery of effective drugs for lipid metabolic disorders based on the DGKθ target.

show abstract

“…On the other hand, hesperidin activated AMPK signaling pathway (Chen et al, 2022), upregulated PI3K/ AKT-Nrf2 signaling (J. Li, Wang, et al, 2021), and inhibited ER stressinduced inflammatory response (Xie et al, 2022).…”

Section: Hesperidinmentioning

confidence: 99%

“…On the one hand, hesperidin altered the makeup of the intestinal microbiota and diversified specific genera, such as Bacteroidota (X. Li, Yao, et al, 2022). On the other hand, hesperidin activated AMPK signaling pathway (Chen et al, 2022), upregulated PI3K/AKT‐Nrf2 signaling (J. Li, Wang, et al, 2021), and inhibited ER stress‐induced inflammatory response (Xie et al, 2022).…”

Section: Mechanisms Of Polyphenolic Compounds Protect Against Hepatic...mentioning

confidence: 99%

Human diet‐derived polyphenolic compounds and hepatic diseases: From therapeutic mechanisms to clinical utilization

Hu,

Zhang,

Wei

et al. 2023

Phytotherapy Research

View full text Add to dashboard Cite

This review focuses on the potential ameliorative effects of polyphenolic compounds derived from human diet on hepatic diseases. It discusses the molecular mechanisms and recent advancements in clinical applications. Edible polyphenols have been found to play a therapeutic role, particularly in liver injury, liver fibrosis, NAFLD/NASH, and HCC. In the regulation of liver injury, polyphenols exhibit anti‐inflammatory and antioxidant effects, primarily targeting the TGF‐β, NF‐κB/TLR4, PI3K/AKT, and Nrf2/HO‐1 signaling pathways. In the regulation of liver fibrosis, polyphenolic compounds effectively reverse the fibrotic process by inhibiting the activation of hepatic stellate cells (HSC). Furthermore, polyphenolic compounds show efficacy against NAFLD/NASH by inhibiting lipid oxidation and accumulation, mediated through the AMPK, SIRT, and PPARγ pathways. Moreover, several polyphenolic compounds exhibit anti‐HCC activity by suppressing tumor cell proliferation and metastasis. This inhibition primarily involves blocking Akt and Wnt signaling, as well as inhibiting the epithelial‐mesenchymal transition (EMT). Additionally, clinical trials and nutritional evidence support the notion that certain polyphenols can improve liver disease and associated metabolic disorders. However, further fundamental research and clinical trials are warranted to validate the efficacy of dietary polyphenols.

show abstract

Hesperidin suppresses ERS-induced inflammation in the pathogenesis of non-alcoholic fatty liver disease

Abstract: Recent studies have confirmed that endoplasmic reticulum stress (ERS) and inflammation play critical roles in the development of . ER is an essential cellular organelle that regulates protein synthesis, folding, and post-translational modification www.aging-us.com

Cited by 22 publications

References 47 publications

Efficacy and safety of dietary polyphenol supplementation in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis

Efficacy and safety of dietary polyphenol supplementation in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis

Rutaecarpin reduces lipids by DGKθ‐dependent activation of PPARα

Human diet‐derived polyphenolic compounds and hepatic diseases: From therapeutic mechanisms to clinical utilization

Contact Info

Product

Resources

About